Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 19/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 7/20 | 0.41 |
| ▸ | PTPRC | P08575 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7165444 | 0.92 | PTPN1 (0.55) | PTPN1PTPN2PTPRC | |
| SCHEMBL7165440 | 0.83 | PTPN1 (0.56) | PTPN1PTPN2PTPRC | |
| SCHEMBL6852050 | 0.81 | PTPN1 (0.47) | PTPN1PTPN2PTPRC | |
| SCHEMBL6850495 | 0.81 | PTPN1 (0.68) | PTPN1PTPN2PTPRC | |
| SCHEMBL7165292 | 0.79 | PTPN1 (0.69) | PTPN1PTPN2PTPRC | |
| SCHEMBL7165563 | 0.77 | PTPN1 (0.77) | PTPN1PTPN2PTPRC | |
| SCHEMBL7886824 | 0.76 | PTPN1 (0.59) | PTPN1PTPN2PTPRC | |
| SCHEMBL7574524 | 0.75 | PTPN1 (0.50) | PTPN1PTPN2PTPRC | |
| SCHEMBL7164053 | 0.73 | PTPN1 (0.56) | PTPN1PTPN2PTPRC | |
| SCHEMBL6850740 | 0.73 | PTPN1 (0.54) | PTPN1PTPN2PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777433-B2 | BIS((DIFLUORO-PHOSPHONATO-METHYL)PHENYL) DERIVATIVES; ANTIDIABETIC AND ANTIOBESITY AGENTS | MERCK FROSST CANADA & CO. (CA) | 2004-08-17 | — | — | US | disclosed |
| US-20030114703-A1 | Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates | MERCK FROSST CANADA LTD. (CA) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114703-A1 | Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates | PTPRO, PTPN1, PTPRS | PTPN1 2/4885PTPN2 22/4885PTPRC 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.